Sharon Klier
Company: Oculis
Job title: Chief Development Officer
Seminars:
Panel Discussion: Comparing Gene Therapy Approaches for Wet AMD: Delivery Methods, Targets, & Therapeutic Potential 2:15 pm
How are intravitreal and subretinal delivery methods impacting treatment precision, effectiveness, and patient experience? What are the implications of targeting VEGF suppression versus complement modulation on efficacy and safety? How can we optimize long-term outcomes by addressing durability, immune response, and safety across different gene therapy approaches?Read more
day: Day Two
Chair’s Closing Remarks 4:15 pm
day: Day Two
Driving forward Phase 3 DIAMOND trials of OCS-01 eye drops, a topical OPTIREACH formulation of high-concentration dexamethasone for DME 10:00 am
Highlighting the OPTIREACH formulation technology and associated benefits Discussing remaining unmet medical needs for DME patient management Exploring the clinical evidence to date on the efficacy and safety of OCS-01 eye drops for DMERead more
day: Day Two
Chair’s Opening Remarks 9:25 am
day: Day Two